Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
citarinostat (ACY-241) / BMS
NCT02886065: A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM	Active, not recruiting	1	19	US	Hiltonol, Poly ICLC, Citarinostat, CC-96241, Lenalidomide, REVLIMID, PVX-410	Massachusetts General Hospital, Celgene, OncoPep, Inc.	Smoldering Multiple Myeloma	09/24	09/24
NCT02635061: Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer	Terminated	1	17	US	ACY-241, Nivolumab, Opdivo	Celgene	Non Small Cell Lung Cancer	01/24	01/24
NCT02400242: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma EHA 2016 May 2016 - May 2016: EHA 2016 P1b data in combination with ricolinostat and dexamethasone for multiple myeloma at ASH 2015 Dec 2015 - Dec 2015: P1b data in combination with ricolinostat and dexamethasone for multiple myeloma at ASH 2015	Terminated	1	85	Europe, US	ACY-241, Histone deacetylase inhibitor, Pomalidomide, immunomodulatory agent, Dexamethasone, corticosteriod	Celgene	Multiple Myeloma	06/24	06/24